BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26416462)

  • 1. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
    Pfirrmann M; Baccarani M; Saussele S; Guilhot J; Cervantes F; Ossenkoppele G; Hoffmann VS; Castagnetti F; Hasford J; Hehlmann R; Simonsson B
    Leukemia; 2016 Jan; 30(1):48-56. PubMed ID: 26416462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simulation study using validated prognostic factors to assess expected long-term survival.
    Pfirrmann M; Hasford J
    Methods Inf Med; 2005; 44(4):577-83. PubMed ID: 16342925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
    Hasford J; Baccarani M; Hoffmann V; Guilhot J; Saussele S; Rosti G; Guilhot F; Porkka K; Ossenkoppele G; Lindoerfer D; Simonsson B; Pfirrmann M; Hehlmann R
    Blood; 2011 Jul; 118(3):686-92. PubMed ID: 21536864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
    Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
    Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
    Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
    da Cunha Vasconcelos F; Mauricio Scheiner MA; Moellman-Coelho A; Mencalha AL; Renault IZ; Rumjanek VM; Maia RC
    Leuk Res; 2016 Dec; 51():3-10. PubMed ID: 27770655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
    Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.
    Pfirrmann M; Lauseker M; Hoffmann VS; Hasford J
    Ann Hematol; 2015 Apr; 94 Suppl 2():S209-18. PubMed ID: 25814087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.
    Ayala M; Ávila E; Domínguez J; Aquino X; Vela J
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):57-62. PubMed ID: 26699851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
    Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J
    Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.